109803-52-3

Upstream product

• 1984-59-4 2,3-dichloroanisole 
• 576-24-9 2,3-dichlorophenol 
• 1940-44-9 4-bromo-2,3-dichlorophenol 
• 74-88-4 methyl iodide 

Downstream Products

• 1190219-72-7 (2,3-dichloro-4-methoxyphenyl)boronic acid 
• 109804-13-9 4-[2,3-Dichloro-4-(cyclopentyl-methyl-carbamoyl)-phenoxy]-butyric acid ethyl ester 
• 109804-10-6 4-(2,3-Dichloro-4-cyclopentylcarbamoyl-phenoxy)-butyric acid ethyl ester 
• 109804-45-7 4-[2,3-Dichloro-4-(cyclopentyl-methyl-carbamoyl)-phenoxy]-butyric acid 
• 109804-42-4 4-(2,3-Dichloro-4-cyclopentylcarbamoyl-phenoxy)-butyric acid 
• 109803-56-7 N-methyl-N-cyclopentyl-2,3-dichloro-4-methoxybenzamide 
• 109803-57-8 N-methyl-N-cyclopentyl-2,3-dichloro-4-hydroxybenzamide 
• 109803-53-4 N-cyclopentyl-2,3-dichloro-4-methoxybenzamide 
• 109803-59-0 N-cyclopentyl-2,3-dichloro-4-hydroxybenzamide 
• 515846-52-3 (R)-[1-(2-{4-[5-(2,3-dichloro-4-methoxy-phenyl)-2-methyl-2H-pyrazol-3-yl]-piperidin-1-yl}-2-oxo-ethylcarbamoyl)-3-methyl-butyl]-carbamic acid tert-butyl ester 
• 76238-31-8 2,3-dichloro-4-methoxybenzoyl chloride 
• 55901-80-9 2,3-dichloro-4-methoxy-benzoic acid 

Relevant academic research and scientific papers

MTH1 INHIBITORS FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE CONDITIONS

A compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment of autoimmune diseases and inflammatory conditions.

Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: An approach for inhibiting protein-protein interactions

Fragment assembly has shown promise for discovering small-molecule antagonists for difficult targets, including protein-protein interactions. Here, we describe a process for identifying a 60 nM inhibitor of the interleukin-2 (IL-2)/IL-2 receptor (IL-2Rα)

Discovery of a potent small molecule IL-2 inhibitor through fragment assembly

Using a site-directed fragment discovery method called tethering, we have identified a 60 nM small molecule antagonist of a cytokine/receptor interaction (IL-2/IL2Rα) with cell-based activity. Starting with a low micromolar hit, we employed a combination

Calcilytic compounds

Novel arylalkylamino compounds exhibiting calcilytic properties are provided.